Literature DB >> 20022779

Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case.

Virginie Dasilva, Véronique Breuil, Patrick Chevallier, Liana Euller-Ziegler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20022779     DOI： 10.1016/j.jbspin.2009.11.005

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


× No keyword cloud information.
  10 in total

1.  Age-associated B Cells Appear in Patients with Granulomatous Lung Diseases.

Authors:  Swati Phalke; Katja Aviszus; Kira Rubtsova; Anatoly Rubtsov; Briana Barkes; Linda Powers; Brenda Warner; James L Crooks; John W Kappler; Evans R Fernández-Pérez; Lisa A Maier; Nabeel Hamzeh; Philippa Marrack
Journal:  Am J Respir Crit Care Med       Date:  2020-10-01       Impact factor: 21.405

Review 2.  Cytokine modulators in the treatment of sarcoidosis.

Authors:  E Bargagli; C Olivieri; P Rottoli
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

3.  M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis.

Authors:  Stefan Prokop; Frank L Heppner; Hans H Goebel; Werner Stenzel
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

Review 4.  Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy?

Authors:  Lindsay J Celada; Wonder P Drake
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

5.  Significant elevation of the levels of B-cell activating factor (BAFF) in patients with sarcoidosis.

Authors:  Masaru Ando; Akihiko Goto; Yukiko Takeno; Mari Yamasue; Kosaku Komiya; Kenji Umeki; Shin-Ichi Nureki; Eishi Miyazaki; Jun-Ichi Kadota
Journal:  Clin Rheumatol       Date:  2018-06-23       Impact factor: 2.980

6.  Rituximab for refractory granulomatous eye disease.

Authors:  Elyse E Lower; Robert P Baughman; Adam H Kaufman
Journal:  Clin Ophthalmol       Date:  2012-10-05

Review 7.  Advances in the diagnosis and treatment of sarcoidosis.

Authors:  Marc A Judson
Journal:  F1000Prime Rep       Date:  2014-10-01

8.  Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels.

Authors:  Anne Saussine; Abdellatif Tazi; Séverine Feuillet; Michel Rybojad; Caroline Juillard; Anne Bergeron; Valérie Dessirier; Fatiha Bouhidel; Anne Janin; Armand Bensussan; Martine Bagot; Jean-David Bouaziz
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

9.  Rituximab in refractory sarcoidosis: a single centre experience.

Authors:  Francesco Cinetto; Nicolò Compagno; Riccardo Scarpa; Giacomo Malipiero; Carlo Agostini
Journal:  Clin Mol Allergy       Date:  2015-09-01

10.  Serum B cell activating factor (BAFF) and sarcoidosis activity.

Authors:  Kamila Hashemzadeh; Maryam Fatemipour; Seyede Zahra Mirfeizi; Mohammadhasan Jokar; Zhaleh Shariati Sarabi; Mohammad-Reza Hatef Fard; Houshang Rafatpanah; Mandana Khodashahi
Journal:  Arch Rheumatol       Date:  2020-09-11       Impact factor: 1.472
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.